Securities code: 600436 securities abbreviation: Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Announcement No.: 2022-009 Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436)
Announcement of resolutions of the first meeting of the seventh board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
The first meeting of the seventh board of directors of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) (hereinafter referred to as “the company”) was held in the conference room on the 22nd floor of the company’s Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) building at 15:30 p.m. on Thursday, January 20, 2022. With the consent of all directors, the time limit for notice was exempted. Meeting notices and proposals shall be delivered by hand and sent by e-mail. There are 9 voting directors and 9 actual voting directors in this meeting. The meeting was presided over by Mr. Lin weiqi, the director. The meeting was held in accordance with the company law, the Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) articles of Association (hereinafter referred to as the “articles of association”) and other relevant provisions, and was legal and effective. The directors present at the meeting voted by means of on-site combined with communication to consider the following proposals: first, the company’s proposal on electing the chairman of the seventh board of directors was considered and adopted; Voting results: 9 in favor, 0 against and 0 abstention.
In order to standardize the company’s operation and improve the corporate governance structure, according to the articles of association and other relevant provisions, the board of directors agreed to elect Mr. Lin Weiqi as the chairman of the seventh board of directors, and the term of office is the same as that of the seventh board of directors (relevant resumes are attached).
According to the articles of association, the chairman is the legal representative of the company. The board of directors of the company authorizes relevant business departments of the company to handle specific matters such as industrial and commercial change registration.
The proposal does not need to be submitted to the general meeting of shareholders of the company for deliberation.
2、 Deliberated and passed the company’s proposal on the appointment of general manager and Secretary of the board of directors;
Voting results: 9 in favor, 0 against and 0 abstention.
Upon the nomination of Mr. Lin weiqi, the chairman of the company, the board of directors agreed to appoint Mr. Huang Jinming as the general manager of the company, Mr. Chen Jipeng as the Secretary of the board of directors, and Ms. Ye Qing as the securities affairs representative of the board of directors. The term of office is the same as that of the seventh board of directors (relevant resumes are attached). The proposal does not need to be submitted to the general meeting of shareholders of the company for deliberation.
3、 Deliberated and passed the company’s proposal on the appointment of deputy general manager and other senior managers; Voting results: 9 in favor, 0 against and 0 abstention.
Nominated by Mr. Huang Jinming, the general manager of the company, the board of directors agreed to appoint Mr. Chen Jipeng and Mr. Liu Congsheng as deputy general managers, Ms. Hong Fei as chief engineer and Mr. Yang Haipeng as chief accountant. The term of office is the same as that of the seventh board of directors (relevant resumes are attached).
The proposal does not need to be submitted to the general meeting of shareholders of the company for deliberation.
4、 Deliberated and passed the proposal of the company on the election of the special committee of the seventh board of directors; Voting results: 9 in favor, 0 against and 0 abstention.
In order to ensure the normal operation of the special committee under the 7th board of directors of the company, according to the changes of the members of the board of directors and nominated by one-third of all directors, the board of directors re elects the members of the audit committee, budget committee, nomination committee, strategy committee and remuneration and assessment committee. The composition of the special committees is as follows:
Strategy Committee:
Lin weiqi (Chairman), Li Guangpei, fan Zhipeng, Huang Jinming, Chen Jipeng
Audit Committee:
Jia Jianjun (Chairman), Du Shouying, Lin weiqi
Nomination Committee:
Li Guangpei (Chairman), fan Zhipeng, Du Shouying, Lin weiqi, Lin liuqiang salary and assessment committee: Fan Zhipeng (Chairman), Lin weiqi, Jia Jianjun, Li Guangpei Budget Committee: Jia Jianjun (Chairman), Du Shouying, Lin liuqiang, Huang Jinming, the term of office of the above members is the same as that of the seventh board of directors of the company. The proposal does not need to be submitted to the general meeting of shareholders of the company for deliberation. It is hereby announced.
Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) board of directors
January 21, 2022
Resume of relevant personnel is attached:
Lin weiqi, male, born in July 1966, CPC member, Bachelor of Arts. From August 1987 to June 1988, he served as a teacher in the English Department of Zhangzhou Normal University, Fujian Province; From June 1988 to July 1988, he served as a cadre of the Education Bureau of Dongshan County, Fujian Province; From July 1988 to September 1996, he successively served as cadre of Foreign Economic Commission of Dongshan County, Fujian Province, deputy chief of foreign investment section and chief of foreign investment section; From September 1996 to December 2001, he successively served as deputy manager and manager of Fujian Dongshan foreign trade company; From December 2001 to March 2014, he successively served as general manager assistant and deputy general manager of Hong Kong Zhanglong Industrial Co., Ltd; From March 2014 to November 2021, he served as member of the Party committee and deputy director of the SASAC of Zhangzhou City, Fujian Province; From November 2021 to now, he has served as secretary of the Party committee and chairman of the Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Committee of the Communist Party of China.
Huang Jinming: born in March 1966, CPC member, master of business administration, senior economist, senior engineer and licensed pharmacist. From July 1987 to January 1997, he successively served as a cadre and deputy director of the workshop of Zhangzhou pharmaceutical factory; From January 1997 to June 1998, he served as the head of Zhangzhou import and Export Corporation (Preparatory); From June 1998 to June 1999, he served as deputy chief of the trade management section of Zhangzhou Foreign Economic Cooperation Bureau; From June 1999 to September 2006, served as the manager of the business department of Zhanglong Industrial Co., Ltd; From September 2006 to December 2015, served as deputy general manager of the company; From December 2015 to April 2016, he served as the executive deputy general manager of the company; From April 2016 to July 2019, he served as a director and executive deputy general manager of the company; From July 2019 to now, he has served as Deputy Secretary of the CPC Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Committee, director and general manager of the company.
Chen Jipeng, born in September 1968, is a CPC member, master of medicine and professor level senior
Engineer, licensed pharmacist. From August 1990 to January 1993, he served as a technician in the Institute of medicine of Zhangzhou pharmaceutical factory; From January 1993 to December 1999, he successively served as a technician and deputy director of the Pharmaceutical Research Institute of Zhangzhou Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) group company (Zhangzhou pharmaceutical factory); From December 1999 to November 2011, he served as the deputy general manager of the company; From November 2011 to September 2017, he served as a director and deputy general manager of the company; Since September 2017, he has served as a director, Secretary of the board of directors and deputy general manager of the company.
Liu Congsheng: male, born in October 1969, CPC member, Bachelor of science, senior economist, deputy chief pharmacist and licensed pharmacist. From August 1991 to December 1999, he served successively as a member of the first workshop of Zhangzhou Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) group company (Zhangzhou pharmaceutical factory), deputy secretary of the general branch of the regiment of the Pharmaceutical Research Institute, deputy secretary of the general branch of the supply and marketing section and deputy chief of the supply and marketing section; From December 1999 to December 2011, he successively served as deputy chief of supply and marketing department, assistant director of operation Department, deputy director of operation Department, director of China marketing department and director of market planning department; From December 2011 to January 2016, he served as deputy director of the company’s marketing center, director of product sales department and director of market planning department; From January 2016 to may 2016, he served as deputy director of the company’s marketing center and director of the market planning department; From May 2016 to October 2017, he served as assistant general manager, deputy director of marketing center and director of market planning department of the company; From October 2017 to June 2020, served as deputy general manager and director of marketing center of the company; From June 2020 to October 2020, served as deputy general manager and director of International Trade Department of the company; From October 2020 to now, he has served as deputy general manager and quality director of the company. Hong Fei: born in December 1971, CPC member, Bachelor of engineering, professor level senior engineer and licensed pharmacist. From August 1993 to December 1999, he served as a technician in the Research Institute of Zhangzhou Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) group company (Zhangzhou pharmaceutical factory); From December 1999 to December 2015, he successively served as technician of the Research Institute, sponsor of the technology center, assistant to the director of the technology center and product research center of the company
Director of development department; From January 2010 to March 2016, he served as deputy director of the company’s technology center and director of product R & D department; From March 2016 to October 2020, he served as the chief engineer of the company. Since October 2020, he has served as the chief engineer and director of the International Trade Department of the company.
Yang Haipeng, born in August 1966, is a member of the Communist Party of China, with an in-service university degree and a senior auditor. From August 1987 to October 1990, he served as the accountant of the financial department of Zhangzhou wool textile printing and dyeing General Factory in Fujian Province; From October 1990 to June 1991, he served as a member of the general audit office of Zhangzhou Audit Bureau, Fujian Province; From June 1991 to July 2019, he served as a member of the financial audit section, industrial transportation audit section, deputy director, director, chief and enterprise audit section of the economic, trade and foreign economic audit section of Zhangzhou Audit Bureau of Fujian Province; From July 2019 to now, he has been the chief accountant of the company.
Ye Qing: born in October 1987, Jiusan Society, Bachelor of management, intermediate accountant. From July 2011 to December 2011, served as the section member of the financial department of the company; From December 2011 to March 2016, served as a clerk of the company’s budget management office; From March 2016 to October 2017, he served as a member of the financial department of the company; From November 2017 to December 2020, he served as the securities affairs representative of the company’s securities investment department; From December 2020 to now, he has served as deputy director of the company’s securities investment department and securities affairs representative.
